Li Jie, Li Qiang, Huang He, Li Yinguang, Li Li, Hou Wenhui, You Zeshan
Department of Gynecology, The Eastern Hospital of the First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong 510700, P.R. China.
Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, P.R. China.
Int J Oncol. 2017 Apr;50(4):1087-1096. doi: 10.3892/ijo.2017.3898. Epub 2017 Mar 7.
MicroRNAs are a class of small non-coding, endogenous RNAs involved in cancer development and progression. MicroRNA-221 (mir-221) has been reported to have both an oncogenic and tumor-suppressive role in human tumors, but the role of miR-221 in ovarian cancer is poorly understood. In the present study, the expression levels of miR-221 and the apoptosis protease activating factor 1 (APAF1) protein in 63 samples of ovarian cancer tissues and the cell lines, IOSE25, A2780, OVCAR3, SKOV3 and 3AO were detected by quantitative reverse-transcription polymerase chain reaction (qRT-PCR) and western blot analysis, respectively. Cell proliferation was measured using cell counting kit-8 (CCK-8); cell migration and invasion were detected using a transwell assay; cell apoptosis was evaluated by flow cytometry and hoechst staining, and a luciferase assay was performed to verify a putative target site of miR-221 in the 3'-UTR of APAF1 mRNA. Expression of miR-221 was upregulated in ovarian cancer tissues. Patients with increased miR-221 expression levels had a reduced disease-free survival (P=0.0014) and overall survival (P=0.0058) compared with those with low miR-221 expression. Transfection of SKOV3 and A2780 cell lines with miR-221 inhibitor induced APAF1 protein expression, suppressed cell proliferation and migration and promoted tumor cell apoptosis. In conclusion, the APAF1 gene was confirmed as a direct target of miR-221 and overexpression of APAF1 suppressed ovarian cancer cell proliferation and induced cell apoptosis in vitro. These findings indicate that miR-221-APAF1 should be studied further as a potential new diagnostic or prognostic biomarker for ovarian cancer.
微小RNA是一类参与癌症发生和发展的小型非编码内源性RNA。据报道,微小RNA-221(mir-221)在人类肿瘤中兼具致癌和抑癌作用,但miR-221在卵巢癌中的作用尚不清楚。在本研究中,分别通过定量逆转录聚合酶链反应(qRT-PCR)和蛋白质免疫印迹分析,检测了63例卵巢癌组织样本以及IOSE25、A2780、OVCAR3、SKOV3和3AO细胞系中miR-221和凋亡蛋白酶激活因子1(APAF1)蛋白的表达水平。使用细胞计数试剂盒-8(CCK-8)测量细胞增殖;使用Transwell实验检测细胞迁移和侵袭;通过流式细胞术和Hoechst染色评估细胞凋亡,并进行荧光素酶测定以验证APAF1 mRNA 3'-UTR中miR-221的假定靶位点。miR-221在卵巢癌组织中的表达上调。与miR-221低表达患者相比,miR-221表达水平升高的患者无病生存期(P = 0.0014)和总生存期(P = 0.0058)缩短。用miR-221抑制剂转染SKOV3和A2780细胞系可诱导APAF1蛋白表达,抑制细胞增殖和迁移,并促进肿瘤细胞凋亡。总之,APAF1基因被确认为miR-221的直接靶标,APAF1的过表达在体外抑制卵巢癌细胞增殖并诱导细胞凋亡。这些发现表明,miR-221-APAF1作为卵巢癌潜在的新诊断或预后生物标志物应进一步研究。